π Chemicals/Chemical Industry (CHM)
Federal lobbying activity for the chemicals/chemical industry issue area
AI Overview
Chemicals/Chemical Industry (CHM) has attracted $98.7M in lobbying spending across 4,629 filings. This issue area sees targeted lobbying from organizations with specific policy interests.
Spending by Year
Top Clients
Top Lobbying Firms
| # | Firm | Revenue |
|---|---|---|
| 1 | Holland & Knight LLP | $6.9M |
| 2 | Wilson & Rome LLP | $5.5M |
| 3 | Bracewell LLP | $4.8M |
| 4 | DC Legislative and Regulatory Services, INC. | $4.7M |
| 5 | Mehlman Consulting, INC. | $4.1M |
| 6 | Ogr | $3.8M |
| 7 | Capitoline Consulting, LLC | $3.2M |
| 8 | Fgs Global (US) LLC (FKA Fgh Holdings LLC) | $3.2M |
| 9 | Lne Group | $3.0M |
| 10 | Cgcn Group, LLC | $2.6M |
| 11 | Fti Government Affairs | $2.4M |
| 12 | Mercury Public Affairs, LLC | $2.2M |
| 13 | Alpine Group Partners, LLC. | $2.1M |
| 14 | Squire Patton Boggs | $1.8M |
| 15 | Hogan Lovells US LLP | $1.6M |
| 16 | Venn Strategies | $1.6M |
| 17 | Akin Gump Strauss Hauer & Feld | $1.4M |
| 18 | Taft Stettinius & Hollister LLP DBA Taft Advisors LLC FKA (Taft, Stettinius & Ho | $1.4M |
| 19 | Association of Equipment Manufacturers | $1.4M |
| 20 | Ballard Partners | $1.3M |
Sample Lobbying Descriptions
β’Federal review of corporate acquisition and corporate tax reform.
β’H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017; S. 1914 - Protecting Access to Diabetes Supplies Act of 2017; Yet to be introduced House and Senate proposal for a regulatory fr
β’Open Competition in Infrastructure Projects
β’issues related to infrastructure and the role of chemistry in economy.
β’Awareness campaign on indoor pool air quality hazards to health and building maintenance
β’Chemical site security, energy supply, chemical regulation, rail competitiveness and hazmat transportation.
β’2018 Farm Bill and potential changes to the Renewable Fuels Standard.
β’General representation pertaining to chemical-manufacturing company and advocacy pertaining to trade remedy disputes
β’Technology to track pharmaceuticals products throughout the supply chain.
β’PRIA S1049, Safer Choice, antimicrobial issues
Related Analysis
Related Investigations
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.